Valproic acid enhances fludarabine-induced apoptosis mediated by ROS and involving decreased AKT and ATM activation in B-cell-lymphoid neoplastic cells

Apoptosis

Volumn 19, Issue 1, 2014, Pages 191-200

  Yoon, Ju Yoon ^a,b   Ishdorj, Ganchimeg ^b   Graham, Bonnie A ^b   Johnston, James B ^a   Gibson, Spencer B ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

AKT; AMT; Apoptosis; CLL; HDAC inhibitors; VPA

Indexed keywords

ATM PROTEIN; CASPASE; CYTOCHROME C; DEATH RECEPTOR; FLUDARABINE; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; VALPROIC ACID;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER PATIENT; CLINICAL TRIAL (TOPIC); DNA DAMAGE; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LYMPHOMA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ADULT; ANTINEOPLASTIC AGENTS; APOPTOSIS; ATAXIA TELANGIECTASIA MUTATED PROTEINS; DRUG SYNERGISM; ENZYME ACTIVATION; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-AKT; REACTIVE OXYGEN SPECIES; TUMOR CELLS, CULTURED; UP-REGULATION; VALPROIC ACID; VIDARABINE;

EID: 84892684876     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-013-0906-7     Document Type: Article

References (42)

1. Elter T, Hallek M, Engert A (2006) Fludarabine in chronic lymphocytic leukaemia. Expert Opin Pharmacother 7(12):1641-1651. doi:10.1517/14656566.7.12. 1641
2. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jager U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Bühler A, Winkler D, Zenz T, Böttcher S, Ritgen M, Mendila M, Kneba M, Döhner H, Stilgenbauer S (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376(9747):1164-1174
3. Mihelic R, Kaufman J, Lonial S, Flowers C (2007) Maintenance therapy in lymphoma. Clin lymphoma Myeloma 7(8):507-513
4. Anderson VR, Perry CM (2007) Fludarabine: a review of its use in non-Hodgkin's lymphoma. Drugs 67(11):1633-1655
5. Elknerova K, Myslivcova D, Lacinova Z, Marinov I, Uherkova L, Stockbauer P (2011) Epigenetic modulation of gene expression of human leukemia cell lines: induction of cell death and senescence. Neoplasma 58(1):35-44
6. Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, Moran M, Lin TS, Liu S, Sklenar AR, Davis ME, Lucas DM, Fischer B, Shank R, Tejaswi SL, Binkley P, Wright J, Chan KK, Grever MR (2005) A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 105(3):959-967. doi:10.1182/blood-2004-05- 1693
7. Blum KA, Advani A, Fernandez L, Van Der Jagt R, Brandwein J, Kambhampati S, Kassis J, Davis M, Bonfils C, Dubay M, Dumouchel J, Drouin M, Lucas DM, Martell RE, Byrd JC (2009) Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. Br J Haematol 147(4):507-514. doi:10.1111/j.1365-2141.2009. 07881.x
8. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20(24):6969-6978
9. Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS (2004) Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 64(3):1079-1086. doi:10.1158/0008- 5472.can-03-0799
10. Bantscheff M, Hopf C, Savitski MM, Dittmann A, Grandi P, Michon A-M, Schlegl J, Abraham Y, Becher I, Bergamini G, Boesche M, Delling M, Dumpelfeld B, Eberhard D, Huthmacher C, Mathieson T, Poeckel D, Reader V, Strunk K, Sweetman G, Kruse U, Neubauer G, Ramsden NG, Drewes G (2011) Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotech 29(3):255-265
11. Bouzar AB, Boxus M, Defoiche J, Berchem G, Macallan D, Pettengell R, Willis F, Burny A, Lagneaux L, Bron D, Chatelain B, Chatelain C, Willems L (2009) Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol 144(1):41-52. doi:10.1111/j.1365-2141.2008.07426.x
12. Lagneaux L, Gillet N, Stamatopoulos B, Delforge A, Dejeneffe M, Massy M, Meuleman N, Kentos A, Martiat P, Willems L, Bron D (2007) Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response. Exp Hematol 35(10):1527-1537. doi:10.1016/j.exphem.2007.06.014
13. Stamatopoulos B, Meuleman N, De Bruyn C, Mineur P, Martiat P, Bron D, Lagneaux L (2009) Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis. Leukemia 23(12):2281-2289
14. Bokelmann I, Mahlknecht U (2008) Valproic acid sensitizes chronic lymphocytic leukemia cells to apoptosis and restores the balance between pro- and antiapoptotic proteins. Mol Med 14(1-2):20-27. doi:10.2119/2007-00084. Bokelmann
15. Johnston JB, Kabore AF, Strutinsky J, Hu X, Paul JT, Kropp DM, Kuschak B, Begleiter A, Gibson SB (2003) Role of the TRAIL// APO2-L death receptors in chlorambucil- and fludarabineinduced apoptosis in chronic lymphocytic leukemia. Oncogene 22(51):8356-8369
16. Riccardi C, Nicoletti I (2006) Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protocols 1(3): 1458-1461
17. Yoon JY, Szwajcer D, Ishdorj G, Benjaminson P, Kumar R, Johnston J, Xaio W, Gibson SB (2013) Synergistic apoptotic response between valproic acid and fludarabine in chronic lymphocytic leukemia (CLL) cells involves the lysosomal protease cathepsin B. Blood Cancer J (Accepted)
18. Kabore AF, Johnston JB, Gibson SB (2004) Changes in the apoptotic and survival signaling in cancer cells and their potential therapeutic implications. Curr Cancer Drug Targets 4(2):147-163
19. Henson ES, Johnston JB, Gibson SB (2008) The role of TRAIL death receptors in the treatment of hematological malignancies. Leuk Lymphoma 49(1):27-35
20. Inoue S, Mai A, Dyer MJS, Cohen GM (2006) Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 66(13):6785-6792. doi:10.1158/0008-5472. can-05-4563
21. Inoue S, MacFarlane M, Harper N, Wheat LMC, Dyer MJS, Cohen GM (2004) Histone deacetylase inhibitors potentiate TNFrelated apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ 11(S2):S193-S206
22. Chen C-S, Weng S-C, Tseng P-H, Lin H-P, Chen C-S (2005) Histone acetylation-independent effect of histone deacetylase inhibitors on akt through the reshuffling of protein phosphatase 1 complexes. J Biol Chem 280(46):38879-38887. doi:10.1074/jbc. M505733200
23. Gupta M, Ansell SM, Novak AJ, Kumar S, Kaufmann SH, Witzig TE (2009) Inhibition of histone deacetylase overcomes rapamycin- mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood 114(14):2926-2935. doi:10.1182/blood-2009-05-220889
24. Lagace DC, Nachtigal MW (2004) Inhibition of histone deacetylase activity by valproic acid blocks adipogenesis. J Biol Chem 279(18):18851-18860. doi:10.1074/jbc.M312795200
25. Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ (2000) Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 164:2200-2206
26. Bhalla S, Balasubramanian S, David K, Sirisawad M, Buggy J, Mauro L, Prachand S, Miller R, Gordon LI, Evens AM (2009) PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-jB mechanisms and is synergistic with bortezomib in lymphoma cells. Clin Cancer Res 15(10):3354-3365. doi:10.1158/1078-0432.ccr-08-2365
27. Dai Y, Rahmani M, Dent P, Grant S (2005) Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-jB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 Activation. Mol Cell Biol 25(13):5429-5444. doi:10.1128/mcb.25.13.5429-5444.2005
28. Horie R, Watanabe M, Okamura T, Taira M, Shoda M, Motoji T, Utsunomiya A, Watanabe T, Higashihara M, Umezawa K (2006) DHMEQ, a new NF-[kappa]B inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells. Leukemia 20(5):800-806
29. Ciccia A, Elledge SJ (2010) The DNA damage response: making it safe to play with knives. Mol Cell 40(2):179-204. doi:10.1016/ j.molcel.2010.09.019
30. Sha K, Winn LM (2010) Characterization of valproic acid-initiated homologous recombination. Birth Defects Res B 89(2):124-132. doi:10.1002/bdrb.20236
31. Harikrishnan KN, Karagiannis TC, Chow MZ, El-Osta A (2008) Effect of valproic acid on radiation-induced DNA damage in euchromatic and heterochromatic compartments. Cell Cycle 7(4):468-476
32. Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NMB, Orr AI, Reaper PM, Jackson SP, Curtin NJ, Smith GCM (2004) Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 64(24):9152-9159. doi:10.1158/0008-5472.can-04-2727
33. Cheung M, Testa JR (2013) Diverse mechanisms of AKT pathway activation in human malignancy. Curr Cancer Drug Targets 13(3):234-244
34. Chen J, Ghazawi F, Bakkar W, Li Q (2006) Valproic acid and butyrate induce apoptosis in human cancer cells through inhibition of gene expression of Akt/protein kinase B. Mol Cancer 5(1):71
35. Mologni L, Cleris L, Magistroni V, Piazza R, Boschelli F, Formelli F, Gambacorti-Passerini C (2009) Valproic acid enhances bosutinib cytotoxicity in colon cancer cells. Int J Cancer 124(8):1990-1996. doi:10.1002/ijc.24158
36. De Sarno P, Li X, Jope RS (2002) Regulation of Akt and glycogen synthase kinase-3b phosphorylation by sodium valproate and lithium. Neuropharmacology 43(7):1158-1164. doi:10.1016/ s0028-3908(02)00215-0
37. Woyach JA, Johnson AJ, Byrd JC (2012) The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood 120(6):1175-1184. doi:10.1182/blood-2012-02-362624
38. Iwasaki H, Huang P, Keating MJ, Plunkett W (1997) Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood 90(1):270-278
39. White EL, Shaddix SC, Brockman RW, Bennett LL (1982) Comparison of the actions of 9-b-d-Arabinofuranosyl-2-fluoroadenine and 9-b-d- Arabinofuranosyladenine on target enzymes from mouse tumor cells. Cancer Res 42(6):2260-2264
40. Rosenwald A, Chuang EY, Davis RE, Wiestner A, Alizadeh AA, Arthur DC, Mitchell JB, Marti GE, Fowler DH, Wilson WH, Staudt LM (2004) Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood 104(5):1428-1434. doi:10.1182/blood-2003-09- 3236
41. Weston VJ, Oldreive CE, Skowronska A, Oscier DG, Pratt G, Dyer MJS, Smith G, Powell JE, Rudzki Z, Kearns P, Moss PAH, Taylor AMR, Stankovic T (2010) The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood 116(22):4578-4587. doi:10.1182/ blood-2010-01-265769
42. Eichhorst B, Goede V, Hallek M (2009) Treatment of elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma 50(2):171-178. doi:10.1080/ 10428190802688517